Casdin Capital, LLC Buys MyoKardia Inc, Sarepta Therapeutics Inc, Blueprint Medicines Corp, Sells Loxo Oncology Inc, iShares Nasdaq Biotechnology Index Fund, Agios Pharmaceuticals Inc

• New Purchases: GILD,
• Added Positions: MYOK, SRPT, BPMC, SAGE, ONCE, ALNY, BOLD, GRTS, BLUE,
• Reduced Positions: AGIO, NVTA, GNMK, GBT,
• Sold Out: LOXO, IBB, QTNT, NTGN,

For the details of Casdin Capital, LLC's stock buys and sells, go to https://www.gurufocus.com/guru/casdin+capital%2C+llc/current-portfolio/portfolio

1. Spark Therapeutics Inc (ONCE) - 940,000 shares, 11.84% of the total portfolio. Shares added by 11.90%
2. Blueprint Medicines Corp (BPMC) - 848,648 shares, 7.51% of the total portfolio. Shares added by 32.60%
3. MyoKardia Inc (MYOK) - 1,285,000 shares, 7.39% of the total portfolio. Shares added by 62.66%
4. Sage Therapeutics Inc (SAGE) - 400,000 shares, 7.04% of the total portfolio. Shares added by 28.21%
5. bluebird bio Inc (BLUE) - 357,500 shares, 6.22% of the total portfolio. Shares added by 8.33%

Casdin Capital, LLC initiated holding in Gilead Sciences Inc. The purchase prices were between $62.53 and $70.05, with an estimated average price of $66.46. The stock is now traded at around $65.30. The impact to a portfolio due to this purchase was 0.58%. The holding were 80,000 shares as of .

Casdin Capital, LLC added to a holding in MyoKardia Inc by 62.66%. The purchase prices were between $39.23 and $55.82, with an estimated average price of $46.05. The stock is now traded at around $47.52. The impact to a portfolio due to this purchase was 2.85%. The holding were 1,285,000 shares as of .

Casdin Capital, LLC added to a holding in Sarepta Therapeutics Inc by 103.33%. The purchase prices were between $106.67 and $151.68, with an estimated average price of $128.32. The stock is now traded at around $119.19. The impact to a portfolio due to this purchase was 2.04%. The holding were 305,000 shares as of .

Casdin Capital, LLC added to a holding in Blueprint Medicines Corp by 32.60%. The purchase prices were between $48.7 and $86.6, with an estimated average price of $73.56. The stock is now traded at around $77.20. The impact to a portfolio due to this purchase was 1.85%. The holding were 848,648 shares as of .

Casdin Capital, LLC added to a holding in Sage Therapeutics Inc by 28.21%. The purchase prices were between $89.33 and $163.65, with an estimated average price of $144.22. The stock is now traded at around $167.05. The impact to a portfolio due to this purchase was 1.55%. The holding were 400,000 shares as of .

Casdin Capital, LLC added to a holding in Alnylam Pharmaceuticals Inc by 25.35%. The purchase prices were between $72.76 and $93.45, with an estimated average price of $83.46. The stock is now traded at around $68.07. The impact to a portfolio due to this purchase was 0.93%. The holding were 445,000 shares as of .

Casdin Capital, LLC added to a holding in Gritstone Oncology Inc by 55.51%. The purchase prices were between $9.97 and $18.96, with an estimated average price of $13.4. The stock is now traded at around $11.04. The impact to a portfolio due to this purchase was 0.59%. The holding were 1,120,586 shares as of .

Casdin Capital, LLC sold out a holding in Loxo Oncology Inc. The sale prices were between $131.02 and $234.75, with an estimated average price of $222.49.

Casdin Capital, LLC sold out a holding in iShares Nasdaq Biotechnology Index Fund. The sale prices were between $96.43 and $115.11, with an estimated average price of $109.52.

Casdin Capital, LLC sold out a holding in Quotient Ltd. The sale prices were between $6 and $11.07, with an estimated average price of $8.75.

Casdin Capital, LLC sold out a holding in Neon Therapeutics Inc. The sale prices were between $4.24 and $6.46, with an estimated average price of $5.22.